genmab
announces
janssen
submitted
supplemental
biologics
license
application
fda
use
darzalex
daratumumab
patients
al
media
release
copenhagen
denmark
september
submitted
sbla
fda
darzalex
daratumumab
combination
bortezomib
cyclophosphamide
dexamethasone
patients
al
amyloidosis
fda
review
oncology
review
pilot
program
project
orbis
submission
based
phase
andromeda
study
triggers
usd
million
milestone
payment
genmab
genmab
nasdaq
gmab
announced
today
licensing
partner
janssen
biotech
janssen
submitted
supplemental
biologics
license
application
sbla
food
drug
administration
fda
seeking
approval
darzalex
daratumumab
subcutaneous
formulation
daratumumab
combination
bortezomib
cyclophosphamide
dexamethasone
vcd
treatment
adult
patients
al
amyloidosis
fda
review
application
oncology
review
rtor
pilot
program
project
orbis
august
genmab
granted
janssen
exclusive
worldwide
license
develop
manufacture
commercialize
daratumumab
submission
sbla
triggers
usd
million
milestone
payment
genmab
extremely
pleased
sbla
darzalex
faspro
patients
al
amyloidosis
reviewed
fda
rtor
pilot
program
project
orbis
hopeful
lead
first
approved
treatment
option
patients
devastating
disease
said
jan
van
de
winkel
chief
executive
officer
genmab
sbla
based
data
phase
andromeda
study
daratumumab
combination
vcd
treatment
patients
newly
diagnosed
al
amyloidosis
data
presented
abstract
european
hematology
association
annual
congress
june
milestone
associated
submission
impact
genmab
guidance
rtor
pilot
project
aim
rtor
pilot
program
explore
efficient
review
process
supplemental
new
drug
applications
sndas
sblas
provide
safe
effective
treatments
patients
early
possible
inclusion
rtor
pilot
program
guarantee
increase
probability
approval
sbla
project
orbis
initiative
fda
oncology
center
excellence
provides
framework
concurrent
submission
review
oncology
products
among
international
partners
andromeda
study
phase
study
included
patients
newly
diagnosed
al
amyloidosis
patients
randomized
receive
treatment
either
daratumumab
combination
bortezomib
proteasome
inhibitor
cyclophosphamide
chemotherapy
dexamethasone
corticosteroid
treatment
vcd
alone
primary
endpoint
study
percentage
patients
achieve
hematologic
complete
response
al
amyloidosis
amyloidosis
disease
occurs
amyloid
proteins
abnormal
proteins
accumulate
tissues
organs
amyloid
proteins
cluster
together
form
deposits
damage
tissues
organs
al
amyloidosis
frequently
affects
heart
kidneys
liver
nervous
system
digestive
tract
currently
cure
existing
approved
therapies
al
amyloidosis
though
treated
chemotherapy
dexamethasone
stem
cell
transplants
supportive
estimated
approximately
new
cases
al
amyloidosis
diagnosed
annually
daratumumab
daratumumab
become
backbone
therapy
treatment
multiple
myeloma
darzalex
intravenous
infusion
indicated
treatment
adult
patients
united
states
combination
carfilzomib
dexamethasone
treatment
patients
relapsed
refractory
multiple
myeloma
received
one
three
previous
lines
therapy
combination
bortezomib
thalidomide
dexamethasone
treatment
patients
newly
diagnosed
multiple
myeloma
eligible
autologous
stem
cell
transplant
combination
lenalidomide
dexamethasone
treatment
patients
newly
diagnosed
multiple
myeloma
ineligible
autologous
stem
cell
transplant
combination
bortezomib
melphalan
prednisone
treatment
patients
newly
diagnosed
multiple
myeloma
ineligible
autologous
stem
cell
transplant
combination
lenalidomide
dexamethasone
bortezomib
dexamethasone
treatment
patients
multiple
myeloma
received
least
one
prior
therapy
combination
pomalidomide
dexamethasone
treatment
patients
multiple
myeloma
received
least
two
prior
therapies
including
lenalidomide
proteasome
inhibitor
pi
monotherapy
treatment
patients
multiple
myeloma
received
least
three
prior
lines
therapy
including
pi
immunomodulatory
agent
pi
immunomodulatory
darzalex
first
monoclonal
antibody
mab
receive
food
drug
administration
fda
approval
treat
multiple
myeloma
darzalex
indicated
treatment
adult
patients
europe
via
intravenous
infusion
subcutaneous
administration
combination
bortezomib
thalidomide
dexamethasone
treatment
patients
newly
diagnosed
multiple
myeloma
eligible
autologous
stem
cell
transplant
combination
lenalidomide
dexamethasone
treatment
patients
newly
diagnosed
multiple
myeloma
ineligible
autologous
stem
cell
transplant
combination
bortezomib
melphalan
prednisone
treatment
adult
patients
newly
diagnosed
multiple
myeloma
ineligible
autologous
stem
cell
transplant
use
combination
lenalidomide
dexamethasone
bortezomib
dexamethasone
treatment
adult
patients
multiple
myeloma
received
least
one
prior
therapy
monotherapy
treatment
adult
patients
relapsed
refractory
multiple
myeloma
whose
prior
therapy
included
pi
immunomodulatory
agent
demonstrated
disease
progression
last
daratumumab
first
subcutaneous
antibody
approved
europe
treatment
multiple
myeloma
option
split
first
infusion
darzalex
two
consecutive
days
approved
europe
japan
darzalex
intravenous
infusion
approved
treatment
adult
patients
combination
lenalidomide
dexamethasone
treatment
patients
newly
diagnosed
multiple
myeloma
ineligible
autologous
stem
cell
transplant
combination
bortezomib
melphalan
prednisone
treatment
patients
newly
diagnosed
multiple
myeloma
ineligible
autologous
stem
cell
transplant
combination
lenalidomide
dexamethasone
bortezomib
dexamethasone
treatment
relapsed
refractory
multiple
myeloma
darzalex
first
human
monoclonal
antibody
reach
market
united
states
europe
japan
information
visit
darzalex
daratumumab
subcutaneous
formulation
daratumumab
approved
united
states
treatment
adult
patients
multiple
myeloma
combination
bortezomib
melphalan
prednisone
newly
diagnosed
patients
ineligible
asct
combination
lenalidomide
dexamethasone
newly
diagnosed
patients
ineligible
asct
patients
relapsed
refractory
multiple
myeloma
received
least
one
prior
therapy
combination
bortezomib
dexamethasone
patients
received
least
one
prior
therapy
monotherapy
patients
received
least
three
prior
lines
therapy
including
pi
immunomodulatory
agent
pi
immunomodulatory
darzalex
faspro
first
subcutaneous
antibody
approved
treatment
multiple
myeloma
daratumumab
human
monoclonal
antibody
mab
binds
high
affinity
molecule
highly
expressed
surface
multiple
myeloma
cells
daratumumab
triggers
person
immune
system
attack
cancer
cells
resulting
rapid
tumor
cell
death
multiple
mechanisms
action
immunomodulatory
effects
addition
direct
tumor
cell
death
via
apoptosis
programmed
cell
death
daratumumab
developed
janssen
biotech
exclusive
worldwide
license
develop
manufacture
commercialize
daratumumab
genmab
comprehensive
clinical
development
program
daratumumab
ongoing
including
multiple
phase
iii
studies
smoldering
relapsed
refractory
frontline
multiple
myeloma
settings
additional
studies
ongoing
planned
assess
potential
daratumumab
malignant
diseases
expressed
amyloidosis
acute
lymphocytic
leukemia
daratumumab
received
two
breakthrough
therapy
designations
fda
certain
indications
multiple
myeloma
including
monotherapy
heavily
pretreated
multiple
myeloma
combination
certain
therapies
treatment
multiple
myeloma
genmab
genmab
publicly
traded
international
biotechnology
company
specializing
creation
development
differentiated
antibody
therapeutics
treatment
cancer
founded
company
creator
following
approved
antibodies
daratumumab
agreement
janssen
biotech
treatment
certain
multiple
myeloma
indications
territories
including
europe
japan
subcutaneous
ofatumumab
agreement
novartis
ag
treatment
adults
relapsing
forms
multiple
sclerosis
teprotumumab
agreement
roche
granting
sublicense
horizon
therapeutics
plc
treatment
thyroid
eye
disease
subcutaneous
formulation
daratumumab
known
darzalex
daratumumab
approved
europe
treatment
adult
patients
certain
multiple
myeloma
indications
first
approved
genmab
created
therapy
ofatumumab
agreement
novartis
ag
approved
treatment
certain
chronic
lymphocytic
leukemia
indications
available
japan
also
available
territories
via
compassionate
use
oncology
access
programs
daratumumab
clinical
development
janssen
treatment
additional
multiple
myeloma
indications
blood
cancers
amyloidosis
genmab
also
broad
clinical
product
pipeline
genmab
technology
base
consists
validated
proprietary
next
generation
antibody
technologies
platform
generation
bispecific
antibodies
platform
creates
effector
function
enhanced
antibodies
platform
combines
two
acting
hexabody
molecules
introduce
selectivity
maximizing
therapeutic
potency
platform
enhances
potential
potency
bispecific
antibodies
hexamerization
company
intends
leverage
technologies
create
opportunities
full
future
products
genmab
alliances
top
tier
pharmaceutical
biotechnology
companies
genmab
headquartered
copenhagen
denmark
sites
utrecht
netherlands
princeton
new
jersey
tokyo
japan
contact
marisol
peron
corporate
vice
president
communications
investor
relations
e
mmp
investor
relations
andrew
carlsen
senior
director
investor
relations
e
acn
media
release
contains
forward
looking
statements
words
believe
expect
anticipate
intend
plan
similar
expressions
identify
forward
looking
statements
actual
results
performance
may
differ
materially
future
results
performance
expressed
implied
statements
important
factors
could
cause
actual
results
performance
differ
materially
include
among
others
risks
associated
clinical
development
products
uncertainties
related
outcome
conduct
clinical
trials
including
unforeseen
safety
issues
uncertainties
related
product
manufacturing
lack
market
acceptance
products
inability
manage
growth
competitive
environment
relation
business
area
markets
inability
attract
retain
suitably
qualified
personnel
unenforceability
lack
protection
patents
proprietary
rights
relationships
affiliated
entities
changes
developments
technology
may
render
products
technologies
obsolete
factors
discussion
risks
please
refer
risk
management
sections
genmab
recent
financial
reports
available
risk
factors
included
genmab
recent
annual
report
form
filings
securities
exchange
commission
sec
available
genmab
undertake
obligation
update
revise
forward
looking
statements
media
release
confirm
statements
reflect
subsequent
events
circumstances
date
made
relation
actual
results
unless
required
law
genmab
subsidiaries
following
trademarks
genmab
genmab
combination
genmab
duobody
combination
duobody
hexabody
combination
hexabody
trademarks
novartis
ag
affiliates
darzalex
trademarks
janssen
pharmaceutica
nv
trademark
horizon
therapeutics
plc
oncology
review
pilot
program
https
accessed
september
project
orbis
food
drug
administration
https
accessed
september
mayo
clinic
website
health
amyloidosis
research
markets
amyloidosis
treatment
market
size
share
trends
analysis
report
treatment
stem
cell
transplant
chemotherapy
supportive
care
surgery
targeted
therapy
country
segment
forecasts
darzalex
prescribing
information
august
https
label
last
accessed
august
darzalex
summary
product
characteristics
available
https
en
medicines
human
epar
darzalex
last
accessed
june
darzalex
faspro
prescribing
information
may
available
https
label
last
accessed
may
de
weers
et
al
daratumumab
novel
therapeutic
human
monoclonal
antibody
induces
killing
multiple
myeloma
hematological
tumors
journal
immunology
overdijk
mb
et
al
phagocytosis
contributes
activity
therapeutic
antibody
daratumumab
lymphoma
multiple
myeloma
mabs
krejcik
md
et
al
daratumumab
depletes
cells
promotes
expansion
skews
repertoire
multiple
myeloma
blood
jansen
jh
et
al
daratumumab
human
antibody
induces
apoptosis
myeloma
tumor
cells
via
fc
crosslinking
blood
abstract
media
release
cvr
lei
code
genmab
kalvebod
brygge
copenhagen
v
denmark
attachment
